Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2015 - 2026)
Axsome Therapeutics recorded quarterly Liabilities and Shareholders Equity of $713.6 million in Q1 2026, up 3.45% quarter-over-quarter from $689.8 million in Q4 2025, and up 19.6% year-over-year from $596.7 million in Q1 2025.
Axsome Therapeutics' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $713.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 19.6% year-over-year to $713.6 million; the TTM figure through Mar 2026 stood at $2.7 billion (up 19.24% YoY), while the FY2025 annual figure was $689.8 million, up 21.34% from the prior year.
- Liabilities and Shareholders Equity came in at $713.6 million for Q1 2026 at Axsome Therapeutics, up from $689.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $713.6 million in Q1 2026 to a low of $88.6 million in Q1 2022.
- A 5-year average of $509.6 million and a median of $568.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity sank 46.94% in 2022 and soared 339.45% in 2023, its largest moves.
- Axsome Therapeutics' Liabilities and Shareholders Equity stood at $331.5 million in 2022, then soared by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024, then gained by 21.34% to $689.8 million in 2025, then advanced by 3.45% to $713.6 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $713.6 million, $689.8 million, and $669.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 713.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 713.61 Mn |
| Dec 31, 2025 | 689.81 Mn |
| Sep 30, 2025 | 669.25 Mn |
| Jun 30, 2025 | 639.79 Mn |
| Mar 31, 2025 | 596.67 Mn |
| Dec 31, 2024 | 568.50 Mn |
| Sep 30, 2024 | 561.46 Mn |
| Jun 30, 2024 | 548.23 Mn |
| Mar 31, 2024 | 545.73 Mn |
| Dec 31, 2023 | 588.24 Mn |
| Sep 30, 2023 | 600.86 Mn |
| Jun 30, 2023 | 611.64 Mn |
| Mar 31, 2023 | 389.18 Mn |
| Dec 31, 2022 | 331.48 Mn |
| Sep 30, 2022 | 338.96 Mn |
| Jun 30, 2022 | 180.56 Mn |
| Mar 31, 2022 | 88.56 Mn |
| Dec 31, 2021 | 87.79 Mn |
| Sep 30, 2021 | 116.60 Mn |
| Jun 30, 2021 | 143.26 Mn |
| Mar 31, 2021 | 166.90 Mn |
| Dec 31, 2020 | 186.13 Mn |
| Sep 30, 2020 | 203.63 Mn |
| Jun 30, 2020 | 190.99 Mn |
| Mar 31, 2020 | 197.80 Mn |
| Dec 31, 2019 | 220.55 Mn |
| Sep 30, 2019 | 44.44 Mn |
| Jun 30, 2019 | 54.78 Mn |
| Mar 31, 2019 | 43.90 Mn |
| Dec 31, 2018 | 15.38 Mn |
| Sep 30, 2018 | 16.13 Mn |
| Jun 30, 2018 | 21.73 Mn |
| Mar 31, 2018 | 27.94 Mn |
| Dec 31, 2017 | 35.56 Mn |
| Sep 30, 2017 | 32.62 Mn |
| Jun 30, 2017 | 39.04 Mn |
| Mar 31, 2017 | 46.41 Mn |
| Dec 31, 2016 | 38.21 Mn |
| Sep 30, 2016 | 34.92 Mn |
| Jun 30, 2016 | 40.01 Mn |
| Mar 31, 2016 | 45.15 Mn |
| Dec 31, 2015 | 49.08 Mn |